Danaher Corporation Stock News

Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.

Sirius XM Holdings Inc. (SIRI) BofA Securities 2024 Health Care Conference Call May 14, 2024 1:40 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Partic

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensiti

Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Secur

WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common sto

WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader

One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.

Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company repor

While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.

PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.

Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e

The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.

Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.

Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the